The CoreQuant
- An editor at The CoreQuant
- New York
I believe in the transformative power of storytelling. Every article I write is an opportunity to connect with you, to share a piece of my world, and to inspire you to see things from a new perspective. Whether it’s through a heartfelt personal essay or a deep dive into a trending topic, my aim is to create content that leaves a lasting impact.
The Latest from The CoreQuant
Why Did Founders Metals, Inc. (TSXV:FDR) Gain 7% on October 1? Antino Gold and the Gold Fields Stake
Ownership consolidation, a major-producer investment and high-grade drilling keep the story in focus. Move on October 1, 2026: +6.9% | Founders Metals, Inc. (TSXV:FDR)
Why Did Quantum eMotion Corp. (TSXV:QNC) Rise 17% on October 1? The Plurilock Acquisition Explained
A proposed acquisition would pair quantum-security technology with an operating cybersecurity business. Move on October 1, 2026: +16.6% | Quantum eMotion Corp. (TSXV:QNC)
Why Did Pulse Seismic Inc. (TSX:PSD) Rise 14% on October 1? Q3 Revenue Up More Than 400%
Preliminary third-quarter licensing revenue came in at more than four times last year's level, but the business is lumpy by nature.
Why Did Beyond Oil Ltd. (TSX:BOIL) Jump 34% on October 1? Global Restaurant Approval Explained
A global vendor approval opens the door to a very large customer base, but revenue still has to follow. Move on October 1, 2026: +34.4% | Beyond Oil Ltd. (TSX:BOIL)
Wall Street Wrap: Pre-Market, October 1, 2026
U.S. futures rise as AI stocks rally on Micron's blockbuster earnings and Alphabet's new Gemini model, even as Treasury yields hit multi-decade highs. Accenture, Vicor, and Rocket Lab lead pre-market gainers, while a global bond selloff and an FTC probe into AI firms add to the day's cross-currents.
Relief Rally or Real Recovery? What Accenture's 16% Jump Means for IT Stocks
Accenture's fiscal fourth-quarter beat and stable guidance lifted the IT services sector 5–10% in pre-market trading, signalling relief that feared AI-driven demand erosion has not yet arrived. Elsewhere, Vicor raised growth guidance on licensing royalties, Alphabet launched a new AI model to muted response, and Roze AI debuted at a 500-plus multiple of revenue—revealing how investors price conviction across quality tiers of evidence.
Pre-Market Biotech Movers: Data, Deals and Listing Risk Set the Tone
Pre-market trading on 1 October 2026 rewarded biotech and pharma companies with measured evidence or contracted certainty—biomarker data, signed payments, resolved compliance issues—while projections and modelled risk drew muted responses. Six names moved on verifiable milestones, revealing how investors price conviction in early-stage science and pipeline strategy.
One Court Ruling Wiped 57% Off Liquidia. Who Else Is Exposed?
On 30 September 2026, a Delaware patent ruling reshuffled $6 billion in market value between two pulmonary hypertension drugmakers, while early-stage clinical data and capital raises tested biotech valuations across intellectual property, clinical evidence and funding. Six stocks moved on legal exposure, trial results and financing terms—revealing how investors price risk differently across the sector.